Table 1.

Clinical and demographic characteristics of patients undergoing staged versus coordinated surgeries

Characteristics	Breast Surgery and BSO
	Coordinated (N=412) n (%)	Staged (N=3816) n (%)	P-value
Age category			0.55
18 - 45	180 (43.7%)	1565 (41.0%)
46 - 55	169 (41.0%)	1619 (42.4%)
>55	63 (15.3%)	632 (16.6%)
Breast Cancer			0.02
Yes	400 (97.1%)	3766 (98.7%)
No	12 (2.9%)	50 (1.3%)
Region			0.11
Northeast	76 (18.5%)	877 (23.0%)
North-central	103 (25.0%)	847 (22.2%)
South	152 (36.9%)	1469 (38.5%)
West	72 (17.5%)	562 (14.7%)
Unknown	9 (2.2%)	61 (1.6%)
Elixhauser Comorbidity Index			0.06
0 – 3	298 (72.3%)	2924 (76.6%)
> 3	114 (27.7%)	892 (23.4%)
Year			<0.01
2010	81 (19.7%)	873 (22.9%)
2011	81 (19.7%)	901 (23.6%)
2012	89 (21.6%)	761 (19.9%)
2013	74 (18.0%)	670 (17.6%)
2014	50 (12.2%)	472 (12.4%)
2015	37 (9.0%)	139 (3.6%)
Breast Surgery			<0.01
Lumpectomy	85 (20.6%)	1328 (34.8%)
Mastectomy	327 (79.4%)	2488 (65.2%)
Reconstruction			<0.01
None	133 (32.3%)	2028 (53.1%)
Post-Lumpectomy Breast Reconstruction	23 (5.6%)	165 (4.3%)
Immediate Implant Placement	32 (7.8%)	230 (6.0%)
Delayed Implant Placement	189 (45.9%)	1172 (30.7%)
Autologous Tissue-Based	26 (6.3%)	173 (4.5%)
Unspecified Reconstruction	9 (2.2%)	48 (1.3%)
BSO Surgical Approach			0.90
Laparoscopic	329 (79.9%)	3030 (79.4%)
Open	83 (20.2%)	786 (20.6%)
Concurrent Hysterectomy			<0.01
Yes	140 (34.0%)	2100 (55.0%)
No	272 (66.0%)	1716 (45.0%)
Axillary Lymph Node Dissection			0.74
Yes	141 (34.2%)	1272 (33.3%)
No	271 (65.8%)	2544 (66.7%)
Neoadjuvant Chemotherapy			<0.01
Yes	109 (26.5%)	596 (15.6%)
No	303 (73.5%)	3220 (84.4%)
Adjuvant Chemotherapy			0.91
Yes	143 (34.7%)	1337 (35.0%)
No	269 (65.2%)	2479 (65.0%)
Adjuvant Endocrine Therapy			0.23
Yes	48 (11.7%)	529 (13.9%)
No	364 (88.4%)	3287 (86.1%)